NCT07134725View on ClinicalTrials.gov

Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

May 22, 2023

Study Completion Date

May 7, 2025

Conditions
COVID - 19
Interventions
BIOLOGICAL

SpiN-Tec MCTI UFMG

Chimeric recombinant protein (SpiN) adjuvanted with CTVad1

OTHER

Active Comparator: Covishield® vaccine

active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)

OTHER

Active Comparator: Comirnaty® vaccine

active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)

Trial Locations (1)

30130-100

Faculdade de Medicina da UFMG - Unidade de Pesquisa Clínica em Vacinas (UPqVac), Belo Horizonte

All Listed Sponsors
collaborator

Oswaldo Cruz Foundation

OTHER

collaborator

The Ministry of Science, Technology and Innovation, Brazil

UNKNOWN

collaborator

Prefeitura de Belo Horizonte (PBH)

UNKNOWN

lead

Federal University of Minas Gerais

OTHER